Utah Retirement Systems Biomarin Pharmaceutical Inc Transaction History

Utah Retirement Systems

$8.7 Billion
Q3 2024

A detailed history of Utah Retirement Systems transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Utah Retirement Systems holds 31,178 shares of BMRN stock, worth $1.92 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

31,178

Previous 31,178 -0.0%

Holding current value

$1.92 Million

Previous $2.57 Million 14.61%

% of portfolio

0.03%

Previous 0.03%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $81,873 - $101,442	-1,100 Reduced 3.41%	31,178 $2.57 Million
Q1 2024 May 15, 2024	SELL	$83.81 - $99.0 $8,381 - $9,900	-100 Reduced 0.31%	32,278 $2.82 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $15,244 - $19,702	200 Added 0.62%	32,378 $3.12 Million
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $17,014 - $18,896	200 Added 0.63%	32,178 $2.85 Million
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $78,012 - $90,270	-900 Reduced 2.74%	31,978 $2.77 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $8,774 - $11,727	100 Added 0.31%	32,878 $3.2 Million
Q4 2022 Feb 15, 2023	SELL	$80.93 - $108.63 $24,279 - $32,589	-300 Reduced 0.91%	32,778 $3.39 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $41,080 - $48,470	500 Added 1.53%	33,078 $2.8 Million
Q1 2022 May 13, 2022	SELL	$74.28 - $92.69 $37,140 - $46,345	-500 Reduced 1.51%	32,578 $2.51 Million
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $7,172 - $9,147	100 Added 0.3%	33,078 $2.92 Million
Q3 2021 Nov 16, 2021	SELL	$74.77 - $85.47 $134,586 - $153,846	-1,800 Reduced 5.18%	32,978 $2.55 Million
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $7,551 - $8,479	100 Added 0.29%	34,778 $2.9 Million
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $112,095 - $136,035	-1,500 Reduced 4.15%	34,678 $2.62 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $108,915 - $135,300	1,500 Added 4.33%	36,178 $3.17 Million
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $21,561 - $39,309	300 Added 0.87%	34,678 $2.64 Million
Q2 2020 Aug 13, 2020	BUY	$79.55 - $124.22 $23,865 - $37,266	300 Added 0.88%	34,378 $4.24 Million
Q4 2019 Feb 12, 2020	BUY	$64.27 - $86.37 $6,427 - $8,637	100 Added 0.29%	34,078 $2.88 Million
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $20,220 - $25,533	300 Added 0.89%	33,978 $2.29 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $25,792 - $30,141	321 Added 0.96%	33,678 $2.89 Million
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $40,079 - $46,943	476 Added 1.45%	33,357 $2.96 Million
Q4 2018 Feb 08, 2019	BUY	$80.14 - $106.07 $8,014 - $10,607	100 Added 0.31%	32,881 $2.8 Million
Q3 2018 Nov 13, 2018	BUY	$93.92 - $105.72 $18,784 - $21,144	200 Added 0.61%	32,781 $3.18 Million
Q2 2018 Aug 10, 2018	BUY	$76.01 - $99.03 $7,601 - $9,903	100 Added 0.31%	32,581 $3.07 Million
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $7,767 - $9,263	100 Added 0.31%	32,481 $2.63 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $32,304 - $38,052	400 Added 1.25%	32,381 $2.89 Million
Q3 2017 Nov 13, 2017	BUY	$80.6 - $94.95 $2.58 Million - $3.04 Million	31,981	31,981 $2.98 Million

Others Institutions Holding BMRN

# of Institutions

641

Shares Held

178M

Call Options Held

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.5B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Utah Retirement Systems, based on Form 13F filings with the SEC.

News

Stay updated on Utah Retirement Systems with notifications on news.

Account

Utah Retirement Systems Biomarin Pharmaceutical Inc Transaction History